Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2019 02/15/2019 02/19/2019 02/20/2019 02/21/2019 Date
84.55(c) 84.32(c) 80.89(c) 79.36(c) 77.31(c) Last
764 863 644 142 967 134 905 105 845 188 Volume
+0.71% -0.27% -4.07% -1.89% -2.58% Change
More quotes
Financials (USD)
Sales 2019 672 M
EBIT 2019 -1,55 M
Net income 2019 -20,9 M
Finance 2019 353 M
Yield 2019 -
Sales 2020 926 M
EBIT 2020 304 M
Net income 2020 262 M
Finance 2020 486 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 29,16
EV / Sales2019 9,92x
EV / Sales2020 7,06x
Capitalization 7 021 M
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are... 
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
02/08NEUROCRINE BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
02/05NEUROCRINE : 4Q Earnings Snapshot
AQ
02/05NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Fina..
AQ
02/05NEUROCRINE BIOSCIENCES : Reports Fourth Quarter and Year-End 2018 Financial Resu..
PR
01/30NEUROCRINE BIOSCIENCES : and Voyager Therapeutics Form Strategic Development and..
AQ
01/30NEUROCRINE BIOSCIENCES : and Voyager Therapeutics Form Strategic Development and..
AQ
01/25ANALYSIS : Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdv..
AQ
01/18NEUROCRINE BIOSCIENCES : New INGREZZA (valbenazine) Analysis Published in the Jo..
AQ
01/17NEUROCRINE BIOSCIENCES : New INGREZZA Analysis Published in the Journal of Affec..
AQ
01/16NEUROCRINE BIOSCIENCES : New INGREZZA® (valbenazine) Analysis Published in the J..
PR
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, IN
More recommendations
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Bio Therapeutic Drugs
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 107 $
Spread / Average Target 38%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.11.13%7 021
GILEAD SCIENCES6.73%86 647
VERTEX PHARMACEUTICALS13.49%48 023
REGENERON PHARMACEUTICALS13.51%45 363
GENMAB-5.57%9 415
SAREPTA THERAPEUTICS INC25.12%9 393